Would you consider HER2-directed therapy in a patient with pretreated metastatic right sided colon adenocarcinoma progressed on FOLFOX-bevacizumab if they are both HER2-neu amplified and have a HER2-neu exon 19 mutation?

Topics: Gastrointestinal Cancers • Medical Oncology • Colorectal Cancer

If so, what agent(s) would you consider given the concurrent amplification and mutation?

Answer from: Medical Oncologist at Academic Institution

Efficacy of HER2 directed therapy in colorectal cancer is under active investigation. HERACLES trial showed an impressive response to trastuzumab and lapatinib in HER2 amplified KRAS-WT cancers. Similarly, MyPathway trial showed a similar response to pertuzumab and trastuzumab (32%). Selection crite...

Comments

Medical Oncologist at St Lukes Cancer Care Assocs
I have never checked for HER-2 mutation in Breast ...

Related Questions